Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights.

ABSTRACT:

Background

Tucidinostat, which is a subtype-selective histone deacetylase inhibitor, has been approved in China for the treatment of hormone receptor-positive (HR⁺) human epidermal growth factor receptor 2-negative (HER2^-) advanced breast cancer (ABC). However, existing evidence mainly stemmed from randomized controlled trials, and might have limitations in representing the complexities of clinical practice and diverse patient populations. Therefore, there is a need to explore the efficacy and optimal therapeutic modality for tucidinostat in real-world clinical settings.

Methods

The objective of this real-world study was to analyze the clinical data of 47 patients with HR⁺/HER2^- ABC who received tucidinostat treatment

SUBMITTER: Suo J 

PROVIDER: S-EPMC10777213 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature